Samalin Investment Counsel’s Teva Pharmaceuticals TEVA Stock Holding History

Samalin Investment Counsel’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,738	Closed	-$87K	–	265
2022 Q3	$87K	Sell	10,738 -5,000	-32%	-$44.2K	0.06%	220
2022 Q2	$118K	Buy	15,738 +523	+3%	+$4.56K	0.08%	215
2022 Q1	$143K	Sell	15,215 -3,500	-19%	-$29.2K	0.09%	234
2021 Q4	$150K	Buy	+18,715	New	+$169K	0.09%	242
2020 Q1	–	Sell	-8,105	Closed	-$79K	–	473
2019 Q4	$79K	Buy	+8,105	New	+$72.4K	0.07%	243

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Samalin Investment Counsel's TEVA Position: Q4 2022 in Review

Samalin Investment Counsel sold out of Teva Pharmaceuticals (TEVA) in Q4 2022, closing a stake of 10,738 shares — an estimated $87K sold.

Samalin Investment Counsel first reported a position in TEVA in Q4 2019 and held it in 5 quarters. The position peaked at $150K in Q4 2021. 422 funds tracked by Wall St. Rank hold TEVA as of Q4 2022.

Samalin Investment Counsel reported no remaining Teva Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Samalin Investment Counsel sold 10,738 Teva Pharmaceuticals shares in Q4 2022, an estimated $87K.
Samalin Investment Counsel first reported a position in Teva Pharmaceuticals in Q4 2019 and held it in 5 quarters.
Samalin Investment Counsel's Teva Pharmaceuticals position peaked at $150K in Q4 2021.
422 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2022.

Based on Samalin Investment Counsel's 13F filing for Q4 2022, filed 10 Feb 2023.